John Strickler
Mayo Clinic Comprehensive Cancer Center · Duke University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name John Strickler as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:59 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07905131 · A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic CancerDaniel Nussbaum, M.D. · not yet recruiting · Pancreatic Ductal Adenocarcinoma (PDAC) · study chair
- Ph1NCT02008383 · Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal CancerJohn Strickler, M.D. · completed · Colorectal Cancer · principal investigator
- Ph1/Ph2NCT01661972 · Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal CancerJohn Strickler, M.D. · completed · Metastatic Colorectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Precision Cancer Med (PCM) & InvestigationP30CA014236 · NCI · DUKE UNIVERSITY · fiscal years 2025 to 2026 · $223,070 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:59 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.N Engl J Med · 2023466 citationsRCR 40.2
- First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.Cancer Immunol Immunother · 2023122 citationsRCR 9.8
- A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.Cancer Med · 201976 citationsRCR 2.6